Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Completed

Conditions studied: Lung Cancer

In brief

RATIONALE: Evaluating specific proteins in the blood may be an effective and noninvasive procedure to help doctors determine if a patient has early non-small cell lung cancer. PURPOSE: This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious (abnormal) stage I lung lesions.

Key facts

Study ID

NCT00077324

Run by

Alliance for Clinical Trials in Oncology

People needed

1000

Starts

2004-02-01

Expected to finish

2011-11-01

Last updated by the study team

2016-07-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must be ≥18 years of age.
• Patient must have a clinically suspicious stage I (cT1-2 N0 M0) lung lesion.
• Patient must have pre-operative imaging procedures within 60 days prior to the date of the lung resection: Helical CT scan of the chest and CT scan of the upper abdomen, including the liver and adrenal glands (with or without IV contrast), as clinically indicated. The helical CT must rule out metastatic disease in the liver and adrenal glands.
• Patient, or the patient's legally acceptable representative, must provide a signed and dated written informed consent PRIOR to registration and any study-related procedures being performed.
• Patient must provide written authorization to allow the use and disclosure of their protected health information. NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient PRIOR to registration and any study-related procedures being performed.
• If patient is a survivor of a prior cancer, the following criteria are met:
• Patient has undergone potentially curative therapy for all prior malignancies,
• No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone),
• Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.

You may not qualify if…

• Patient has undergone previous lung resection within the preceding 30 days.
• Patient has received prior chemotherapy or radiotherapy.
• Patient has had a blood product transfusion of any kind within the past 60 days of the operative procedure.

Where it is running

• John Muir/Mount Diablo Cancer Center - Concord Campus — Concord, California, United States
• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Glendale Memorial Hospital Comprehensive Cancer Center — Glendale, California, United States
• Veterans Affairs Medical Center - Loma Linda (Pettis) — Loma Linda, California, United States
• Sutter Cancer Center at Roseville Medical Center — Roseville, California, United States
• Sutter Cancer Center — Sacramento, California, United States
• John Muir/Mt. Diablo Comprehensive Cancer Center — Walnut Creek, California, United States
• Praxair Cancer Center at Danbury Hospital — Danbury, Connecticut, United States
• George Washington University Medical Center — Washington D.C., District of Columbia, United States
• Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital — Fort Lauderdale, Florida, United States
• Winship Cancer Institute of Emory University — Altanta, Georgia, United States
• MBCCOP-Medical College of Georgia Cancer Center — Augusta, Georgia, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• Cancer Institute at St. John's Hospital — Springfield, Illinois, United States
• Regional Cancer Center at Memorial Medical Center — Springfield, Illinois, United States
• Southern Illinois University School of Medicine — Springfield, Illinois, United States
• St. Francis Hospital and Health Centers - Beech Grove Campus — Beech Grove, Indiana, United States
• Reid Hospital & Health Care Services, Incorporated — Richmond, Indiana, United States
• Jewish Hospital — Louisville, Kentucky, United States
• Greater Baltimore Medical Center Cancer Center — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• William Beaumont Hospital - Royal Oak Campus — Royal Oak, Michigan, United States
• Veterans Affairs Medical Center - Minneapolis — Minneapolis, Minnesota, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.